May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
The Vasodilatory Effect of Juxta-Arteriolar Microinjection of Endothelin-A Receptor Inhibitor in Healthy and in Acute Branch Retinal Vein Occlusion Minipig Retinae
Author Affiliations & Notes
  • A. N. Stangos
    Division of Ophthalmology, Department of Clinical Neurosciences, University Hospitals of Geneva, Geneva, Switzerland
  • I. K. Petropoulos
    Division of Ophthalmology, Department of Clinical Neurosciences, University Hospitals of Geneva, Geneva, Switzerland
  • N. Gilodi
    Division of Ophthalmology, Department of Clinical Neurosciences, University Hospitals of Geneva, Geneva, Switzerland
  • C. J. Pournaras
    Division of Ophthalmology, Department of Clinical Neurosciences, University Hospitals of Geneva, Geneva, Switzerland
  • Footnotes
    Commercial Relationships A.N. Stangos, None; I.K. Petropoulos, None; N. Gilodi, None; C.J. Pournaras, None.
  • Footnotes
    Support Swiss National Science Foundation Grant no. 3200B0-105809
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2268. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. N. Stangos, I. K. Petropoulos, N. Gilodi, C. J. Pournaras; The Vasodilatory Effect of Juxta-Arteriolar Microinjection of Endothelin-A Receptor Inhibitor in Healthy and in Acute Branch Retinal Vein Occlusion Minipig Retinae. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2268.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To investigate the vasoactive effect of endothelin-A receptor inhibitor (BQ-123) on the retinal arteriolar vasculature in normal and in acute branch retinal vein occlusion (BRVO) minipig retinae.

Methods:: Under systemic anesthesia, 6 normal eyes of 6 minipigs and 5 eyes of 5 minipigs with acute experimental BRVO were evaluated in our laboratory according to the ARVO resolution on the use of animals in research. A standardized photodynamic method was used for BRVO. One eye of each animal was subjected to the experiment according to best quality of fundus visualization. In all eyes, a slow, continuous microinjection of 30 µl BQ-123 (0.67 µg/ml) was performed approximately 50-100 µm from the retinal arteriole, avoiding exerting pressure on retina’s anatomical structures. Eyes were not vitrectomized. After the microinjection, the retinae were observed for changes in vessels’ diameter. The procedure was continuously recorded in real time. Throughout the procedure, the animals’ vital signs were monitored.

Results:: Overall (n=11), an increase of 18.56% and 26.45% in arteriolar diameter was evidenced 5 and 15 minutes respectively after BQ-123 microinjection. When separately examining normal (n=6) versus OBVR (n=5) eyes, the increase in arteriolar diameter 5 minutes post injection was 16.75% versus 19.86% respectively (P=0.491), whereas the increase in arteriolar diameter 15 minutes post injection was 25.14% versus 27.4% (P=0.591).

Conclusions:: Our results demonstrate a significant increase in retinal arteriolar diameter after juxta-arteriolar BQ-123 microinjection, both in healthy and in acute OBVR retinae. There was no statistically significant difference between the amount of vasodilation exerted by BQ-123 on healthy and on BRVO retinae. This vasodilatory effect can be potentially beneficial in counterbalancing or reversing the arteriolar vasoconstriction that settles within hours following BRVO, with subsequent improvement of arteriolar blood flow.

Keywords: vascular occlusion/vascular occlusive disease • ischemia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×